POTASSIUM ACETATE (potassium acetate) by Pfizer is clinical pharmacology as the principal cation of the intracellular fluid, potassium plays an important role in fluid and electrolyte balance. First approved in 1984.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
Potassium acetate is an injectable electrolyte replacement therapy that restores intracellular and extracellular potassium balance in patients with hypokalemia. It works by supplementing potassium, the principal intracellular cation, while the acetate component serves as an alternate source of bicarbonate through hepatic metabolism. This dual mechanism makes it particularly valuable in patients with acid-base disturbances or severe liver impairment.
Product approaching loss of exclusivity with low linked job count signals shrinking brand team and transition from growth-phase hiring to maintenance-focused roles.
CLINICAL PHARMACOLOGY As the principal cation of the intracellular fluid, potassium plays an important role in fluid and electrolyte balance. The normal potassium concentration in the intracellular fluid compartment is about 160 mEq/liter. The normal serum potassium range is 3.5 to 5.0 mEq/liter.…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on potassium acetate at LOE represents a defensive, operational-focused career path rather than growth opportunity. Roles emphasize cost management, supply continuity, and institutional relationships in a commoditized market.
Worked on POTASSIUM ACETATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo